DAFNA Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

DAFNA Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273K	Hold	64,492	–	–	0.05%	83
2026 Q1	$299K	Hold	64,492	–	–	0.07%	79
2025 Q4	$457K	Hold	64,492	–	–	0.11%	70
2025 Q3	$499K	Hold	64,492	–	–	0.12%	69
2025 Q2	$448K	Sell	64,492 -16,307	-20%	-$130K	0.12%	67
2025 Q1	$686K	Sell	80,799 -40,000	-33%	-$471K	0.19%	68
2024 Q4	$1.69M	Sell	120,799 -1,401	-1%	-$30K	0.43%	46
2024 Q3	$2.77M	Hold	122,200	–	–	0.65%	40
2024 Q2	$2.47M	Hold	122,200	–	–	0.59%	39
2024 Q1	$3.04M	Hold	122,200	–	–	0.69%	36
2023 Q4	$2.21M	Hold	122,200	–	–	0.53%	41
2023 Q3	$2.45M	Hold	122,200	–	–	0.76%	34
2023 Q2	$3.12M	Hold	122,200	–	–	0.85%	34
2023 Q1	$2.6M	Hold	122,200	–	–	0.78%	36
2022 Q4	$3.62M	Hold	122,200	–	–	1.02%	31
2022 Q3	$2.84M	Sell	122,200 -9,000	-7%	-$214K	0.76%	35
2022 Q2	$2.2M	Buy	131,200 +78,000	+147%	+$1.64M	0.6%	42
2022 Q1	$2.33M	Buy	+53,200	New	+$2.48M	0.61%	45

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

DAFNA Capital Management's BCYC Position: Q2 2026 in Review

DAFNA Capital Management held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 64,492 shares worth $273K. The position accounts for 0.05% of the portfolio, ranked #83.

DAFNA Capital Management first reported a position in BCYC in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.62M in Q4 2022. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

DAFNA Capital Management held 64,492 shares of Bicycle Therapeutics worth $273K as of Q2 2026.
DAFNA Capital Management left its Bicycle Therapeutics share count unchanged in Q2 2026.
Bicycle Therapeutics made up 0.05% of DAFNA Capital Management's portfolio in Q2 2026, its #83 holding.
DAFNA Capital Management first reported a position in Bicycle Therapeutics in Q1 2022 and has held it in 18 quarters since.
DAFNA Capital Management's Bicycle Therapeutics position peaked at $3.62M in Q4 2022.
103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.